| 
DRL is a resource to local and national basic and clinical
researchers in areas of method development and validation.
Our expertise in clinical chemistry includes genomic- and
proteomic-based techniques; immunoassay; therapeutic drug
monitoring; and toxicology. We provide collaborative, fee-for-service,
and other consultative arrangements.
Developement of Biological Markers of
Disease
Bayer Diagnostics (01/03 to 01/04 )
(PI: R. Valdes; Co-PI: SA Jortani)
Developement of Digoxin Immunoassays
Abbott Laboratories Diagnostics Division (12/02 to 11/03)
(PI: R Valdes: Co-Investigator: SA Jortani)
Genesis Blood Glucose System
- Project 239001)
Bayer Diagnostics (05/02 to 08/02)
(PI: R Valdes; Co-investigator: SA Jortani)
Evaluation of Potential Interference
Caused by ALT, AST, and GGT in the New Bayer HCV RNA Assay
Bayer Diagnostics (02/02 to 03/02)
(PI: R. Valdes; Co-investigator: SA Jortani)
Development of Research-Based Immunoassays
for Mammalian Cardenolides
Dade Behring Inc. (01/01 to 01/03)
(PI: R.Valdes; Co-investigator: SA Jortani)
Investigation of urinary trypsin
inhibitor as marker of bacterial infection
Bayer Diagnostics (01/01 to 07/02)
(PI: R. Valdes; Co-investigator: SA Jortani)
Development of HPLC Technology
for Measurement of Cyclosporin A and its Metabolites
Roche Diagnostics (07/00 to 10/00)
(PI: R. Valdes)
Sensitivity of REMEDI in screening
serum for drugs in an emergency tertiary care facility
BioRad Laboratories (4/97 to 10/97)
(Co-PI: R. Valdes; Co-PI: MW Linder; Investigator: G Bosse)
Biochemical markers for diagnosis
of acute myocardial infarction
Biosite Diagnostics (11/96 to 8/97)
(PI: R. Valdes)
Evaluation of X-Link interface
software
Dupont Medical Products (3/96 to 6/96)
(Co-PI: R. Valdes, Jr.; PI: J. Miller)
Discrepant digoxin results: Reference
lab consortium agreement
Boehringer Mannheim Corporation (11/95 to 10/97)
(PI: R. Valdes)
Assessment of new digoxin immunoassay
on IMX analyzer
Abbott Diagnostics (4/95 to 9/95)
(PI: R. Valdes)
Analytical assessment of discrepant
digoxin results
Bayer (Miles, Inc) Diagnostics (3/95 to 2/97)
(PI: R. Valdes)
Assessment of cardiac troponin-I
for myocardial infarction
Dade International (2/95 to 8/95)
(PI: R. Valdes, Jr.; Co-Investigators: et al.)
Evaluation of Chemistry Analyzer
XL instrumentation
Dupont Medical Products (1/95 to 7/95)
(PI: R. Valdes, Jr.; Co-PI: J. Miller)
Performance assessment of AxSYM
immunoassay system
Abbott Diagnostics (11/94 to 9/95)
(PI: R. Valdes)
|
